Jenny Bailey, CEO of Ferryx tells Lu Rahman how its leading product FX856 came to life and how it’s a game-changer for inflammatory bowel disease since it can act during active inflammation.  Ferryx is an innovative bio-tech start-up. It is a University of Bristol spin-out with a focus on gut health and IBD in particular. Its mission is to […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!